Skip to main content
. 2017 Jan 23;12(1):e0170362. doi: 10.1371/journal.pone.0170362

Fig 1. Flow chart of the enrolled participants.

Fig 1

CHB, chronic hepatitis B; TDF, tenofovir disoproxil fumarate; HCC, hepatocellular carcinoma; LAM-R, lamivudine-resistant; ADV-R, adefovir-resistant; MDR, multidrug-resistant.